How much does dotalizumab (Jemperli) cost?

Dotalizumab (Jemperli) is an immunotherapy drug used to treat a specific type of ovarian cancer, those with a highly unstable microsatellite mismatch (dMMR) or lacking DNA mismatch repair (dMMR).

Dotalizumab It is not yet available in the country, and it is not included in medical insurance. Patients cannot purchase it domestically and need to purchase dotalizumab through overseas channels. There are only original drugs available abroad, mainly from the United States, and the price is as high as about 50,000 yuan.

Dotalizumab is an immune checkpoint inhibitor that enhances the immune system's attack on cancer cells by inhibiting the signaling pathway on the PD-1 (programmed death 1) receptor. PD-1Normally inhibits immune cells from recognizing and attacking abnormal cells, and dotalizumab works to relieve this inhibition, allowing the immune system to destroy cancer cells more effectively.

The primary indication for dotalizumab is ovarian cancer with highly unstable microsatellite mismatches or deficientDNAmismatch repair. These patients' tumor cells often have extensive DNA damage and mutations, which makes it easier for the immune system to recognize and attack the cancer cells. Therefore, dotilizumab provides a new treatment option for these patients, especially when conventional treatments are ineffective or intolerable.

However, dotilizumab may also cause some side effects, including fatigue, nausea, skin inflammation, gastrointestinal discomfort, etc. More serious side effects may include immune-related inflammation, such as hepatitis, pneumonia, thyroiditis, etc. Therefore, patients receiving dotalizumab need to have their health status closely monitored and any potential side effects promptly addressed.